Profile
Paul Shin formerly worked at Avanir Pharmaceuticals, Inc., as Vice President-Research & Development Operations from 2011 to 2016, Intercept Pharmaceuticals, Inc., as Vice President-Global Clinical Operations from 2018 to 2020, Nestle Health Science SA, as SVP-Global Research & Development Operations from 2016 to 2018, and 89bio, Inc., as VP-Research & Development Operations from 2024 to 2025.
Mr. Shin received his undergraduate degree from the University of California.
Former positions of Paul Shin
| Companies | Position | End |
|---|---|---|
| 89BIO, INC. | Chief Operating Officer | 05/08/2024 |
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2020 |
Nestle Health Science SA
Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Manufactures nutritional and supplement health products | Chief Tech/Sci/R&D Officer | 01/01/2018 |
| AVANIR PHARMACEUTICALS INC | Chief Tech/Sci/R&D Officer | 01/01/2016 |
Training of Paul Shin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products for the treatment of nervous system disorder | Health Technology |
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
Nestle Health Science SA
Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Manufactures nutritional and supplement health products | Health Technology |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
89bio, Inc.
89bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
- Stock Market
- Insiders
- Paul Shin
















